ClinicalTrials.gg

Program

WIN378

A development code.

Its studies are mostly in Pulmonary Disease, Chronic Obstructive · Asthma, led by Windward Bio.

Furthest: phase 2, since Jul 25, 20252 company-led studies, 2 open or runningNext primary completion: Dec 17, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Windward Bio22 open or runningphase 2since Jul 25, 2025Jul 25, 2025Dec 17, 2027phase 2 · NCT07646587

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 25, 2025First study: phase 2 study in AsthmaFirst studyNCT07120503 · 600 planned · United States, Argentina, Australia and more
  2. Jun 2, 2026Phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT07646587 · 105 planned · United States, Argentina

Ahead

  1. Dec 17, 2027Primary completion: phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT07646587
  2. Oct 1, 2028Primary completion: phase 2 study in AsthmaNCT07120503

TargetBeta

TSLP →read by rule
“WIN378 is a fully human, long-acting monoclonal antibody that targets the ligand of thymic stromal lymphopoietin (TSLP), blocking its activity and thereby reducing airway inflammation and improving COPD control over an extended dosing interval”study text, by rule · the study

Other programs on TSLP

ProgramCompanyFurthest phaseStudies
tezepelumabruleAstraZenecaphase 434
tilrekimigPfizerphase 311
lunsekimigSanofiphase 310
felcorekibartGlaxoSmithKlinephase 39
SHR-1905Jiangsu HengRui Medicinephase 37
TQC2731Sino Biopharmaceuticalphase 37
CDX-622ruleCelldex Therapeuticsphase 12
HXN-1013ruleHelixon Biotechnology (Suzhou)phase 11
HY6725ruleNewsoara Biopharmaphase 11

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07646587Pulmonary Disease, Chronic Obstructive · United States, Argentina2RecruitingDec 17, 2027105
NCT07120503Asthma · United States, Argentina, Australia and more2RecruitingOct 1, 2028600

How it is read

Names in the registry

  • “WIN378”, 2 entries

Codes read as this program: WIN378.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.